PAH – Talk Bio

Actionable Insights Powered by AI

Merck’s Winrevair Slashes Morbidity and Mortality Risk in Pulmonary Arterial Hypertension

3 weeks ago talkbio0Tagged Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III ZENITH trial, Pulmonary arterial hypertension, Winrevair

Winrevair, pulmonary arterial hypertension (PAH), Phase III ZENITH trial, morbidity, mortality, Merck

Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns

4 months ago talkbio0Tagged concerns, dosing, KER-012, PAH, Phase II TROPOS trial, Pulmonary arterial hypertension, Safety, Suspensions

Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial

Merck’s Winrevair Demonstrates Significant Mortality Benefit in Pulmonary Arterial Hypertension Patients

5 months ago talkbio0Tagged Benefit, Co., Mortality Vital Statistics, PAH, Pulmonary arterial hypertension, Sotatercept, Winrevair

Winrevair, Pulmonary Arterial Hypertension (PAH), Mortality Benefit, Sotatercept, Merck & Co.

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

5 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality